JFG
ARQT icon

Jefferies Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Jefferies Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,500
Closed -$377K – 1430
2024
Q2 		$377K Buy
+40,500
New +$366K ﹤0.01% 1045

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jefferies Financial Group's ARQT Position: Q2 2025 in Review

Jefferies Financial Group sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 86,925 shares — an estimated $1.36M sold.

Jefferies Financial Group first reported a position in ARQT in Q3 2024 and held it in 3 quarters. The position peaked at $1.53M in Q4 2024. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Jefferies Financial Group reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 86,925 Arcutis Biotherapeutics shares in Q2 2025, an estimated $1.36M.
  • Jefferies Financial Group first reported a position in Arcutis Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Jefferies Financial Group's Arcutis Biotherapeutics position peaked at $1.53M in Q4 2024.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Jefferies Financial Group's 13F filing for Q2 2025, filed 12 Aug 2025.